leisure time -WSS

leisure time

author：knowledge 2025-08-11 08:01:19 - browse：68

3d rendered medically accurate illustration of the adrenal gland – biotech and pharma coverage from STAT — Adobe

SAN DIEGO — Neurocrine Biosciences announced on Tuesday that an experimental drug for congenital adrenal hyperplasia succeeded in a late-stage trial, bringing the company a step closer to treating patients with a rare and serious set of genetic disorders that alters their ability to produce key hormones.

In the Phase 3 study, known as CAHtalyst, 182 adults were randomly assigned to receive a placebo or crinecerfont, an oral drug Neurocrine developed to lower male sex hormones patients with the disease produce in excess. Researchers found that, compared to those on placebo, participants who took crinecerfont needed a significantly lower dose of the current standard-of-care treatment, glucocorticoids, after 24 weeks of treatment that they did at the study’s start. And about 63% of participants who took crinecerfont were able to lower their dose of glucocorticoids to levels researchers think would be safer for prolonged use, compared to 18% of those on the placebo.

Neurocine, a San Diego biotech focused on treating rare neurological and endocrine diseases, believes the drug could allow people living with congenital adrenal hyperplasia, or CAH, to avoid some of the more serious side effects of glucocorticoids by allowing them to take lower doses. Long-term use of high doses of these drugs can cause patients to gain weight and put them at risk of diabetes, heart disease, and osteoporosis.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Affirmative action in medical school literally saved lives
Next article： Stem cell treatment guidelines are released by FDA

focus

WSS

A rare thyroid diagnosis led to unexpected, all

Update the Apgar Score to remove skin color

The (many) problems with a new study criticizing cancer screening

Covid hospitalizations on the rise, Humana says

Trump surgeon general acknowledges mistakes during Covid

ALS advocates say criticism of new drugs misses bigger picture

Wikipedia

leisure time

focus

Walensky prepares to leave CDC — and Congress — behind

High breast density mammograms need follow

23andMe had bad news about my health. I wish a person had delivered it

Dog Aging Project founders on what lies ahead after losing funding

What does generative AI mean for health care? We asked experts

Dog Aging Project founders on what lies ahead after losing funding

Cancer drug shortages should be causing more outrage

Snackable artificial intelligence, expert AI, and the pharma industry

In age of alternative facts, a scholarly course on calling out crap

Maisha Meds is a PBM, but don't call it that

entertainment

Dana Farber says 6 studies to be retracted and 31 corrected

What causes osteoarthritis? Researchers study link to brain protein

A pediatrician calls for Congress to pass the child tax credit deal

A rare thyroid diagnosis led to unexpected, all

Sanofi to acquire U.S. biotech Inhibrx in $2.2 billion deal

How to fix cancer clinical trials' diversity problem

knowledge

hotspot

focus

entertainment